Z Trademark

Trademark Overview

On Thursday, September 18, 2014, a trademark application was filed for Z with the United States Patent and Trademark Office. The USPTO has given the Z trademark a serial number of 86398253. The federal status of this trademark filing is SECTION 8 & 15 - ACCEPTED AND ACKNOWLEDGED as of Wednesday, February 17, 2021. This trademark is owned by Zynerba Pharmaceuticals, Inc.. The Z trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Pharmaceutical and therapeutic drug development services; pharmaceutical and therapeutic drug research and development
z

General Information

Serial Number86398253
Word MarkZ
Filing DateThursday, September 18, 2014
Status702 - SECTION 8 & 15 - ACCEPTED AND ACKNOWLEDGED
Status DateWednesday, February 17, 2021
Registration Number4847465
Registration DateTuesday, November 3, 2015
Mark Drawing3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, February 3, 2015

Trademark Statements

Description of MarkThe mark consists of the letter "Z" with a partial circle crossing through the "Z".
Pseudo MarkZYNERBA
Indication of Colors claimedColor is not claimed as a feature of the mark.
Goods and ServicesPharmaceutical and therapeutic drug development services; pharmaceutical and therapeutic drug research and development

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, September 25, 2014
Primary Code042
First Use Anywhere DateFriday, July 31, 2015
First Use In Commerce DateFriday, July 31, 2015

Trademark Owner History

Party NameZynerba Pharmaceuticals, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressDevon, PA 19333
Party NameZynerba Pharmaceuticals, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressDevon, PA 19333
Party NameZynerba Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressLexington, KY 40505

Trademark Events

Event DateEvent Description
Thursday, September 25, 2014NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, September 22, 2014NEW APPLICATION ENTERED
Monday, December 15, 2014ASSIGNED TO EXAMINER
Wednesday, January 14, 2015NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, February 3, 2015PUBLISHED FOR OPPOSITION
Tuesday, March 31, 2015NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, September 22, 2015TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, September 22, 2015TEAS STATEMENT OF USE RECEIVED
Tuesday, September 22, 2015USE AMENDMENT FILED
Saturday, September 26, 2015CASE ASSIGNED TO INTENT TO USE PARALEGAL
Saturday, September 26, 2015STATEMENT OF USE PROCESSING COMPLETE
Tuesday, September 29, 2015ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Friday, September 26, 2014NOTICE OF DESIGN SEARCH CODE E-MAILED
Tuesday, December 16, 2014APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, February 3, 2015OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, September 30, 2015NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Wednesday, December 6, 2017TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, November 3, 2020COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Wednesday, November 4, 2020TEAS SECTION 8 & 15 RECEIVED
Tuesday, November 3, 2015REGISTERED-PRINCIPAL REGISTER
Wednesday, December 6, 2017ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, February 14, 2018TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, February 16, 2021CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Wednesday, February 17, 2021NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Sunday, November 3, 2024COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Wednesday, February 17, 2021REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.

Related Keywords

development pharmaceutical drug therapeutic research services